| Company Name: | Alexza Pharmaceuticals, Inc. | | Ticker Symbol: | ALXA | | | WWW Address: | www.alexza.com |
| CEO: | Thomas B. King | | No. of Employees: | 63 |
| Common Issue Type: | CS | | Business Description: | Alexza Pharmaceuticals, Inc. is a pharmaceutical company focused on the research, development and commercialization of novel proprietary products for the acute treatment of central nervous system conditions.
|
| | | Industry Information: | DRUGS - Drug Manufacturers - Other [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 4.55 |  0.03 | 4.5 | 4.9 | 4.51 | 4.74 | 4.50 | - |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 71.9 | 15.8 | 1.75 | -2.24 | 0.00 | 0.0 | 0.0 | 6.65 - 2.55 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 4.61 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 71.9 | mil |
| Latest Shares Outstanding | 15.8 | mil |
| Earnings pS (EPS) | -2.24 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | | % |
| Revenue per Employee | 64,603 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 13.9 | mil |
| Float as % of Shares Outstanding | 88.2 | % |
| Foreign Sales | | mil |
| Domestic Sales | | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 478.90 | % |
| Research & Devlopment (R&D) as % of Revenue | 790.30 | % |
| Gross Profit Margin | 0.0 | % |
| EBITDA Margin | 0.0 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 0.1 | % |
| Return on Assets (ROA) | -167.6 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | 278.5 | % |
| Current Ratio | 0.6 | |
| Leverage Ratio (Assets/Equity) | 0.0 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | -0.48 | $ |
| Cash pS | 0.74 | $ |
| Book-Value pS | 0.00 | $ |
| Tangible Book-Value pS | -1.11 | $ |
| Cash Flow pS | -2.83 | $ |
| Free Cash Flow pS | -1.87 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 0.00 | |
| Price/Tangible Book Ratio | -4.17 | |
| Price/Cash Flow | -1.6 | |
| Price/Free Cash Flow | -2.5 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 1.3 | 102 | 2,379 | 9,408 |
| 4 Weeks | 4.86 | 4.30 | 4.39 | 5.0 | 107 | 3,106 | 55,903 |
| 13 Weeks | 6.65 | 4.21 | 4.55 | 1.3 | 97 | 4,267 | 264,550 |
| 26 Weeks | 6.65 | 4.03 | 5.84 | -21.1 | 68 | 4,518 | 555,662 |
| 52 Weeks | 6.65 | 2.55 | 2.75 | 67.6 | 138 | 5,150 | 1,277,103 |
| YTD | 6.65 | 4.03 | - | -6.9 | 81 | 3,507 | 396,313 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 4.60 | 4.52 | 4.56 | 4.67 | 4.71 | 1.75 | 1.72 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 0.00 | 0.0 | 0.00 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | -46.33 | NA | -44.12 |
| R&D | -16.28 | NA | -16.16 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -61.3 | -61.3 | -28.1 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | -0.91 | -0.91 | 3.76 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 12.08 |
| Current Ratio | 1.3 |
| Quick Ratio (Acid Test) | 0.9 |
| Liquidity Ratio (Cash) | 1.22 |
| Receivables Turnover | 0.8 |
| Average Collection Period | 450 |
| Working Capital/Equity | 190.4 |
| Working Capital pS | 0.31 |
| Cash-Flow pS | -1.47 |
| Free Cash-Flow pS | -1.19 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | -2.12 |
| Financial Leverage Ratio (Assets/Equity) | 15.8 |
| Debt Ratio | 93.7 |
| Total Debt/Equity (Gearing Ratio) | 2.51 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 748.5 |
| LT Debt/Total Liabilities | 0.0 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 6.53 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 5.83 |
| Tobin's Q Ratio | 1.80 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -3.05 |
| Enterprise Value (EV)/Free Cash Flow | -2.90 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | -4.17 |
| Price/Book Ratio - LTM | 0.00 |
| Price/Cash Flow Ratio | -1.6 |
| Price/Free Cash Flow Ratio - LTM | -2.5 |
| Price/Sales Ratio | 24.98 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 1.19 |
| Tangible Book Value pS - LTM | -1.11 |
| Book Value pS - LTM | 0.00 |
| Capital Invested pS | 0.16 |
| Cash pS - LTM | 0.74 |
| Cash Flow pS - LTM | -2.83 |
| Free Cash Flow pS - LTM | -1.87 |
| Earnings pS (EPS) | -2.24 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -459.29 |
| Free Cash Flow Margin 5YEAR AVG | -2,708.48 |
| Net Profit Margin | 0.0 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | 1.58 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 1.58 |
| Return on Capital Invested (ROCI) | -1087.4 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -677.6 |
| Assets Productivity | 0.10 |
| Return on Assets (ROA) | -69.0 |
| Return on Assets (ROA) - 5YEAR AVRG. | -80.5 |
| Gross Profit Margin | 0.0 |
| Gross Profit Margin - 5YEAR AVRG. | 0.0 |
| EBITDA Margin - LTM | 0.0 |
| EBIT Margin - LTM | 0.0 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | 0.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | |
| Revenue per Employee | 64,603 |
| Net Income per Employee | -444,095 |
| Average Collection Period | |
| Receivables Turnover | 0.8 |
| Day's Inventory Turnover Ratio | |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | 52.75 |
| Assets/Revenue | 10.00 |
| Net Working Capital Turnover | 0.83 |
| Fixed Assets Turnover | 0.24 |
| Total Assets Turnover | 0.1 |
| Revenue per $ Cash | 0.23 |
| Revenue per $ Plant | 0.25 |
| Revenue per $ Common Equity | 1.58 |
| Revenue per $ Capital Invested | 1.58 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 272.6 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 111.7 |
| Research & Devlopment (R&D) as % of Revenue | 536.8 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 536.8 |
|
|  
|
| |
 |  |
